| Date | Title | Description |
| 14.09.2018 | Icagen Raises $7.25 Million, Bringing its Total to $20.75 Million for 2018 | Drug development company Icagen Inc. raised $7.25 million from one investor, according to a filing with the Securities and Exchange Commission.
The Durham-based company filed a Form D to report the offering and disclosed that the funds will... |
| 14.09.2018 | Icagen Raises $7.25 Million, Bringing its Total to $20.75 Million for 2018 | Drug development company Icagen Inc. raised $7.25 million from one investor, according to a filing with the Securities and Exchange Commission.
The Durham-based company filed a Form D to report the offering and disclosed that the funds will... |
| 13.04.2018 | Durham-based Icagen Raises $2 Million | Icagen Inc., a pharmaceutical development company, has raised $2 million, according to a filing with the Securities and Exchange Commission.
The money was raised in the form of equity and options from one investor, according to the filing. ... |
| 13.04.2018 | Durham-based Icagen Raises $2 Million | Icagen Inc., a pharmaceutical development company, has raised $2 million, according to a filing with the Securities and Exchange Commission.
The money was raised in the form of equity and options from one investor, according to the filing. ... |
| 30.04.2017 | Durham’s Icagen Raises $1.5 Million in Private Offering | Icagen Inc., a Durham-based drug discovery company, sold $1.5 million in shares in a private offering, according to a Securities and Exchange Commission filing.
Icagen filed the Form D on April 27. The company stated that the proceeds may b... |
| 30.04.2017 | Durham’s Icagen Raises $1.5 Million in Private Offering | Icagen Inc., a Durham-based drug discovery company, sold $1.5 million in shares in a private offering, according to a Securities and Exchange Commission filing.
Icagen filed the Form D on April 27. The company stated that the proceeds may b... |
| 13.09.2011 | PFE gives ICGN shareholders last chance to accept $56M deal | “The subsequent offering period is now scheduled to expire at 6 p.m., New York City time, on Monday, Sept. 19, 2011, and will not be extended again,” the company said in a statement.
As of Sept. 12, more than 5 million shares of Durham, Nor... |
| 06.09.2011 | Pfizer secures enough shares for Icagen acquisition | Pfizer’s initial offer for Durham, North Carolina-based Icagen had been challenged by some Icagen shareholders as too low. They contended that the $6 per share price undervalued the potential of Icagen’s drug pipeline of pain treatment cand... |
| 02.09.2011 | Pfizer’s Icagen offer extended again; now expires at 6 p.m. | Today’s extension is the second in as many days. As of midnight Thursday, the deadline of the first extension, 49.6 percent of fully diluted shares of Icagen were tendered for the sale. Pfizer needs a majority of shares to move ahead with t... |
| 01.09.2011 | Pfizer extends Icagen offer; remains just shy of shares needed for deal | The agreement for a Pfizer acquisition of Icagen was announced on July 20, a cash deal valued at $6 per share. That price was a more than 22 percent discount to the July 19 close of $7.75. Icagen shares traded at around $2.40 per share unti... |
| 26.08.2011 | PFE to ICGN shareholders: ‘$6 per share is our best and final price’ | In June, speculation that Pfizer was interested in buying drug partner Icagen sent the Durham, North Carolina-based developmental stage pain drug company’s stock from $2.40 per share to a July 19 peak close of $7.75 per share. Pfizer’s acqu... |
| 22.08.2011 | At-the-market offering for biotech funding? Review 4 quick perspectives | That’s just over 2 percent of the $8.2 billion raised through ATM offerings in 2010. Nonetheless, companies like Icagen, Novavax (NASDAQ:NVAX) in Maryland and Zalicus (NASDAQ:ZLCS) in Massachusetts all used it this year.
Brinson Patrick fou... |
| 12.08.2011 | Investors blocking PFE’s $56M ICGN bid say firm’s value could be $165M | Two Icagen (NASDAQ:ICGN) institutional investors opposed to Pfizer‘s (NYSE:PFE) $56 million offer for the pain drug development company now say the company’s value should be nearly three times that amount.
Merlin Nexus and New Leaf Venture ... |
| 10.08.2011 | Pfizer-Icagen deal: PFE’s $56M cash offer for ICGN beat two other bids | Pfizer‘s (NYSE:PFE) $56 million offer to acquire Icagen (NASDAQ:ICGN) followed a mostly fruitless courtship dating back five years that ultimately saw the pharma giant beat out two others who vied for all or part of the pain drug company.
P... |
| 29.07.2011 | Pfizer-Icagen deal faces problem: Merlin Nexus opposes price | Pfizer’s (NYSE:PFE) $56 million bid to acquire Icagen (NASDAQ:ICGN) faces a big hurdle — two of Icagen’s largest shareholders.
Merlin Nexus and New Leaf Venture Partners, two firms holding Icagen stock, submitted a July 28 letter to the Ica... |
| 20.07.2011 | Pfizer acquires Icagen for $56 million | Pfizer and Icagen have partnered for the last four years to develop Icagen’s pain drug compounds. Icagen’s research focuses on compounds that modulate ion channels, protein structures found in the cells of the human body. The companies expl... |
| 28.06.2011 | Pfizer-Icagen merger: What ICGN could bring to PFE’s portfolio | Here are the areas targeted by Icagen’s ion channel research:
Pain and epilepsy. The ICA-105665 is being developed jointly with Pfizer and Icagen. The compound has been through Phase 1 studies, and a hold the U.S. Food and Drug Administrati... |
| 27.06.2011 | Could NC biotech Icagen get acquired by Pfizer? | Icagen stock price more than doubled to $5 per share on Friday as investors reacted positively to Pfizer’s interest in the Durham, North Carolina-based company. The price tumbled back to around $2.40 per share and then rebounded again this ... |
| 26.04.2011 | N.C. pharma Icagen names Krafte chief scientific officer | Icagen is collaborating with Pfizer (NYSE:PFE) to develop drug candidates to treat pain. Icagen’s compounds effect ion channels, which are protein structures found in the cells of the human body. A one-year development agreement with Pfizer... |
| 29.03.2011 | North Carolina pharma R&D funding: A snapshot of 2010 | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 07.03.2011 | Pfizer milestone payment for pain treatment lifts Icagen revenue | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 02.02.2011 | Icagen’s epilepsy drug study gets FDA OK to resume | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| - | Icagen’s epilepsy drug study gets FDA OK to resume | Drug development company Icagen is now free to move ahead with clinical trials on its epilepsy drug candidate after regulators removed a hold placed on the compound for safety concerns.
Last September, Icagen (NASDAQ:ICGN), based in North C... |
| - | Pfizer-Icagen deal: PFE’s $56M cash offer for ICGN beat two other bids | Pfizer‘s (NYSE:PFE) $56 million offer to acquire Icagen (NASDAQ:ICGN) followed a mostly fruitless courtship dating back five years that ultimately saw the pharma giant beat out two others who vied for all or part of the pain drug company.
P... |
| - | Pfizer-Icagen deal faces problem: Merlin Nexus opposes price | Pfizer’s (NYSE:PFE) $56 million bid to acquire Icagen (NASDAQ:ICGN) faces a big hurdle — two of Icagen’s largest shareholders.
Merlin Nexus and New Leaf Venture Partners, two firms holding Icagen stock, submitted a July 28 letter to the Ica... |
| - | Pfizer extends Icagen offer; remains just shy of shares needed for deal | Pfizer‘s (NYSE:PFE) $56 million offer for Icagen (NASDAQ:ICGN) has been extended one more day as the pharmaceutical giant remains just shy of the minimum shares needed to execute the acquisition.
Unless there is another extension, Pfizer’s ... |
| - | Pfizer’s Icagen offer extended again; now expires at 6 p.m. | Icagen‘s (NASDAQ:ICGN) sale to Pfizer (NYSE:PFE) hangs in the balance by 39,799 shares.
That’s the minimum number of shares that need to be tendered for the $56 million sale to proceed. Pfizer extended to 6 p.m. today the expiration date of... |
| - | N.C. pharma Icagen names Krafte chief scientific officer | North Carolina biopharmaceutical company Icagen (NASDAQ:ICGN) has promoted executive Douglas Krafte to the newly created position of chief scientific officer.
Krafte has been vice president of biology and scientific affairs at the Durham, N... |
| - | Could NC biotech Icagen get acquired by Pfizer? | Pfizer (NYSE:PFE) is taking a hard look at acquiring the NC biotech company Icagen (NASDAQ:ICGN) in a move that could bring a slate of pain drug candidates into the pipeline of the world’s largest pharmaceutical company.
Pfizer has disclose... |
| - | At-the-market offering for biotech funding? Review 4 quick perspectives | When it needed to raise $3.7 million for ongoing clinical trials earlier this year, Icagen (NASDAQ:ICGN) chose a road less traveled.
The company naturally raised the money in the public markets. But it used an approach known as an at-the-ma... |
| - | North Carolina pharma R&D funding: A snapshot of 2010 | Research and development spending dollars reached a record $67.4 billion in 2010, a $1.5 billion increase compared with 2009.
North Carolina’s life science companies are certainly part of that mix. A look at the annual reports from public c... |
| - | Pfizer secures enough shares for Icagen acquisition | Pfizer‘s (NYSE:PFE) Icagen (NASDAQ:ICGN) acquisition is a go.
After two extensions last week, Pfizer announced today that it has enough shares tendered for sale for the $56 million cash deal to proceed at the price of $6 per share. As of th... |
| - | Investors blocking PFE’s $56M ICGN bid say firm’s value could be $165M | Two Icagen (NASDAQ:ICGN) institutional investors opposed to Pfizer‘s (NYSE:PFE) $56 million offer for the pain drug development company now say the company’s value should be nearly three times that amount.
Merlin Nexus and New Leaf Venture ... |
| - | PFE gives ICGN shareholders last chance to accept $56M deal | Nearly one-third of Icagen (NASDAQ:ICGN) shareholders have yet to accept Pfizer‘s (NYSE:PFE) $56 million offer for the pain drug development company and the pharmaceutical giant is giving them one last chance.
The expiration date for the of... |
| - | Pfizer acquires Icagen for $56 million | Pfizer (NYSE:PFE) will acquire North Carolina drug development company Icagen (NASDAQ:ICGN) for $56 million in a move to bolster its own pain drug pipeline.
Under terms of the agreement, Pfizer, which already owns about 11 percent of Resear... |
| - | Pfizer-Icagen merger: What ICGN could bring to PFE’s portfolio | Pfizer (NYSE:PFE) is now talking about a possible acquisition of Icagen (NASDAQ:ICGN). But, already, Pfizer is Icagen’s primary supporter.
Icagen, which is based in Durham, North Carolina, has relied on a 2007 partnership with Pfizer to dev... |
| - | Pfizer milestone payment for pain treatment lifts Icagen revenue | A Pfizer milestone payment of $1 million in the fourth quarter helped boost Icagen’s revenue to $2.3 million, up 64 percent from $1.4 million a year ago, according to financial results released Monday.
Durham, North Carolina-based Icagen (N... |
| - | PFE to ICGN shareholders: ‘$6 per share is our best and final price’ | Pfizer (NYSE:PFE) will not raise its offer to acquire Icagen (NASDAQ:ICGN).
The pharmaceutical giant sent a letter to Icagen’s board of directors today holding firm on its purchase price of $6 per share, which amounts to $56 million. Dougla... |
